DALLAH HEALTHCARE COMPANY |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 163.2 SAR | -1.33% |
|
-3.89% | -5.01% |
| Mar. 20 | Dallah Healthcare Company Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| Mar. 14 | Dallah Healthcare Logs Higher FY23 Net Profit, Revenue | MT |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 3,335 | 4,126 | 6,759 | 13,320 | 16,782 | 15,942 | - | - |
| Enterprise Value (EV) 1 | 4,287 | 5,510 | 8,440 | 15,060 | 18,520 | 17,610 | 17,615 | 17,316 |
| P/E ratio | 23.2 x | 42.7 x | 26.2 x | 48.5 x | 46.4 x | 41.3 x | 30.8 x | 27.6 x |
| Yield | 2.56% | 1.55% | 2% | - | - | 1.41% | 1.85% | 1.82% |
| Capitalization / Revenue | 2.66 x | 3.13 x | 3.21 x | 5.35 x | 5.7 x | 4.94 x | 4.45 x | 4.12 x |
| EV / Revenue | 3.42 x | 4.18 x | 4.01 x | 6.05 x | 6.29 x | 5.46 x | 4.92 x | 4.47 x |
| EV / EBITDA | 17.4 x | 25 x | 19.1 x | 28.1 x | 29.3 x | 26.1 x | 22.6 x | 20.8 x |
| EV / FCF | 40.4 x | 102 x | 34.3 x | 55.9 x | 55.9 x | 70.4 x | 47.4 x | 31.8 x |
| FCF Yield | 2.47% | 0.98% | 2.91% | 1.79% | 1.79% | 1.42% | 2.11% | 3.15% |
| Price to Book | 2.23 x | 2.36 x | 3.62 x | 6.69 x | 4.82 x | 4.49 x | 4.52 x | 4.35 x |
| Nbr of stocks (in thousands) | 85,512 | 85,512 | 90,000 | 90,000 | 97,681 | 97,681 | - | - |
| Reference price 2 | 39.00 | 48.25 | 75.10 | 148.0 | 171.8 | 163.2 | 163.2 | 163.2 |
| Announcement Date | 3/1/20 | 3/25/21 | 3/22/22 | 3/20/23 | 3/14/24 | - | - | - |
1SAR in Million2SAR
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 1,252 | 1,318 | 2,105 | 2,488 | 2,943 | 3,225 | 3,583 | 3,873 |
| EBITDA 1 | 247.1 | 220.2 | 443 | 536.7 | 631.9 | 674.1 | 778.2 | 834.4 |
| EBIT 1 | 154.4 | 125.2 | 365 | 422.4 | 506.3 | 542 | 618.4 | 650.4 |
| Operating Margin | 12.33% | 9.49% | 17.34% | 16.98% | 17.2% | 16.81% | 17.26% | 16.79% |
| Earnings before Tax (EBT) 1 | 151.6 | 113.5 | 291.8 | 329.1 | 400.3 | 458.3 | 581.1 | 615.2 |
| Net income 1 | 146.9 | 97.13 | 258.6 | 274.5 | 360.1 | 425.8 | 505.4 | 590.6 |
| Net margin | 11.73% | 7.37% | 12.29% | 11.03% | 12.24% | 13.2% | 14.11% | 15.25% |
| EPS 2 | 1.683 | 1.130 | 2.870 | 3.050 | 3.700 | 3.954 | 5.298 | 5.923 |
| Free Cash Flow 1 | 106.1 | 53.93 | 245.9 | 269.4 | 331.3 | 250 | 371.3 | 545 |
| FCF margin | 8.47% | 4.09% | 11.68% | 10.83% | 11.26% | 7.75% | 10.36% | 14.07% |
| FCF Conversion (EBITDA) | 42.93% | 24.49% | 55.51% | 50.2% | 52.42% | 37.09% | 47.71% | 65.32% |
| FCF Conversion (Net income) | 72.19% | 55.52% | 95.1% | 98.17% | 91.99% | 58.71% | 73.46% | 92.29% |
| Dividend per Share 2 | 1.000 | 0.7500 | 1.500 | - | - | 2.308 | 3.017 | 2.964 |
| Announcement Date | 3/1/20 | 3/25/21 | 3/22/22 | 3/20/23 | 3/14/24 | - | - | - |
1SAR in Million2SAR
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 544.1 | 575 | 609.4 | 583.8 | 600.9 | 693.9 | 716.6 | 670.4 | 749.8 | 806 | 790.7 | 737.5 | 862.3 | 678.7 |
| EBITDA | - | - | 138.6 | - | - | - | - | 132.7 | - | 145.4 | - | - | - | - |
| EBIT 1 | 69.95 | 154 | 115.1 | 96.68 | 84.19 | 131.6 | 138.1 | 102.9 | 131 | 134.3 | 137.3 | 131.2 | 153.4 | 120.8 |
| Operating Margin | 12.86% | 26.78% | 18.89% | 16.56% | 14.01% | 18.97% | 19.27% | 15.35% | 17.47% | 16.67% | 17.36% | 17.79% | 17.79% | 17.79% |
| Earnings before Tax (EBT) | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net income 1 | 84.72 | 73.73 | 82.63 | 69.52 | 43.87 | 78.44 | 94.66 | 53.01 | 98.87 | 113.6 | 109.8 | - | - | - |
| Net margin | 15.57% | 12.82% | 13.56% | 11.91% | 7.3% | 11.3% | 13.21% | 7.91% | 13.19% | 14.1% | 13.88% | - | - | - |
| EPS 2 | - | - | - | - | 0.4900 | 0.8700 | - | 0.5400 | - | 1.170 | 1.120 | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 11/8/21 | 3/22/22 | 5/19/22 | 8/18/22 | 11/10/22 | 3/20/23 | 5/24/23 | 8/8/23 | 11/9/23 | 3/14/24 | - | - | - | - |
1SAR in Million2SAR
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | 952 | 1,384 | 1,681 | 1,740 | 1,738 | 1,669 | 1,674 | 1,374 |
| Net Cash position 1 | - | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | 3.852 x | 6.285 x | 3.795 x | 3.241 x | 2.75 x | 2.476 x | 2.151 x | 1.647 x |
| Free Cash Flow 1 | 106 | 53.9 | 246 | 269 | 331 | 250 | 371 | 545 |
| ROE (net income / shareholders' equity) | 9.41% | 5.92% | 14.1% | 14.2% | 13.9% | 12.8% | 15.3% | 15.8% |
| ROA (Net income/ Total Assets) | 5.23% | 2.81% | 5.89% | 5.74% | 6.45% | 7.2% | 7.93% | 8.95% |
| Assets 1 | 2,810 | 3,452 | 4,388 | 4,783 | 5,582 | 5,914 | 6,371 | 6,599 |
| Book Value Per Share 2 | 17.50 | 20.40 | 20.70 | 22.10 | 35.70 | 36.40 | 36.10 | 37.50 |
| Cash Flow per Share 2 | 3.530 | 2.130 | 4.020 | 4.910 | 6.430 | 5.170 | 6.140 | 6.760 |
| Capex 1 | 201 | 129 | 116 | 173 | 295 | 208 | 265 | 187 |
| Capex / Sales | 16.06% | 9.81% | 5.49% | 6.94% | 10.01% | 6.44% | 7.41% | 4.83% |
| Announcement Date | 3/1/20 | 3/25/21 | 3/22/22 | 3/20/23 | 3/14/24 | - | - | - |
1SAR in Million2SAR
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
UNDERPERFORM
Number of Analysts
10
Last Close Price
163.2
SAR
Average target price
154.4
SAR
Spread / Average Target
-5.40%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -5.01% | 4.25B | |
| -20.16% | 16.21B | |
| +4.50% | 12.44B | |
| +3.98% | 11.58B | |
| +9.72% | 10.79B | |
| +23.61% | 8.26B | |
| -2.19% | 7.68B | |
| +20.75% | 7.2B | |
| +4.49% | 6.67B | |
| +50.89% | 4.66B |
- Stock Market
- Equities
- 4004 Stock
- Financials Dallah Healthcare Company
